Intended for healthcare professionals. Supported by an independent medical education grant from Helsinn Therapeutics (U.S.), Inc.

Integrating tumor microenvironment biology with clinical impact: Evolving understanding of therapeutic approaches for MF‑CTCL

Join Dr. Larisa J. Geskin and leading experts for this free, on-demand, interactive, CME-accredited symposium examining the role of the tumor microenvironment (TME) in mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL).

Explore how tumor microenvironment biology influences disease progression and therapeutic response, and how these insights can inform precision-informed treatment selection.

The free, on-demand webcast will be available from April 2026.

Integrating tumor microenvironment biology with clinical impact: Evolving understanding of therapeutic approaches for MF‑CTCL
CME: 1.0 credits available
Duration: 60 minutes
Release date: Available from April 2026

On-demand CME-accredited webcast with Dr. Larisa J. Geskin. Free to access from April 2026!

Larisa J. Geskin

Dr. Larisa J. Geskin, MD, FAAD

Columbia University Irving Medical Center, New York, NY, USA
View biography and disclosures
Open biography modal for Larisa J. Geskin
Francine Foss

Dr. Francine Foss, MD

Yale School of Medicine, New Haven, CT, USA
View biography and disclosures
Open biography modal for Francine Foss
Christiane Querfeld

Dr. Christiane Querfeld, MD, PhD

City of Hope Comprehensive Cancer Center, Duarte, CA, USA
View biography and disclosures
Open biography modal for Christiane Querfeld
Sima Rozati

Dr. Sima Rozati, MD, PhD

Johns Hopkins University School of Medicine, Baltimore, MD, USA
View biography and disclosures
Open biography modal for Sima Rozati
  1. Increase knowledge and confidence in interpreting MF-CTCL tumor microenvironment biology, recognizing its influence on disease progression and therapy response, and applying this understanding to guide evidence-based clinical decision-making
  2. Increase knowledge and confidence in evaluating the cytotoxic and immunomodulatory mechanisms of skin-directed therapies, understanding how these agents modulate the TME to reduce malignant cell burden, enhance antitumor immunity, and guide evidence-based, durable management of MF-CTCL

Introduction
Dr. Larisa J. Geskin (5 minutes)

Understanding the TME in MF-CTCL
Dr. Christiane Querfeld (15 minutes)

Cytotoxic mechanisms of skin-directed therapies
Dr. Sima Rozati (15 minutes)

Immunomodulatory and TME-modulating effects of skin-directed therapies
Dr. Francine Foss (15 minutes)

Closing remarks and Q&A
Dr. Larisa J. Geskin (10 minutes)

In support of improving patient care, these activities have been planned and implemented by the Postgraduate Institute for Medicine and Springer Health+ IME. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Joint Accreditation Provider logo

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

Postgraduate Institute for Medicine logo

 

As part of the planning committee, the Postgraduate Institute for Medicine and Springer Health+ IME planners and staff have no financial relationships to disclose.

All relevant financial relationships of the faculty have been mitigated.

In partnership with the United States Cutaneous Lymphoma Consortium (USCLC). This symposium was presented and recorded as part of the USCLC Annual Workshop 2026: Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics and Future Directions.

Dermapathologists​, dermatologists, medical oncologists, oncodermatologists

Supported by an independent medical education grant from Helsinn Therapeutics (U.S.), Inc.

On-demand CME-accredited webcast with Dr. Larisa J. Geskin. Free to access from April 2026!

© 2026 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.
Banner image © 2026 Springer Healthcare LLC. Springer Healthcare is part of Springer Nature. All rights reserved., Teaser image © 2026 Springer Healthcare LLC. Springer Healthcare is part of Springer Nature. All rights reserved., CME icon © 2026 Springer Healthcare LLC. Springer Healthcare is part of Springer Nature. All rights reserved., Larisa J. Geskin © 2026 Larisa J. Geskin, Francine Foss © 2026 Francine Foss, Christine Querfeld © 2026 Christine Querfeld, Sima Rozati © 2026 Sima Rozati, Postgraduate Institute for Medicine (PIM) logo © 2026 Postgraduate Institute for Medicine, United States Cuteneous Lymphoma Consortium (USCLC) logo © 2026 United States Cutaneous Lymphoma Consortium (USCLC)
Programs